Study finds lab-created antibody effective in preventing severe respiratory illness in infants
New Delhi: A
monoclonal antibody
-- a protein created in a lab which mimics the work of a natural antibody -- could be highly effective in preventing severe RSV, a respiratory infection and major cause of serious illness in infants, according to a research.
Findings of the study, published in The Lancet Child and Adolescent Health journal, show that injecting infants with the antibody '
nirsevimab
' reduces risk of RSV-related hospitalisations by 83 per cent and intensive care admissions by 81 per cent.
Infant immunisation programmes could, therefore, help address the health and economic burden due to RSV in the high-risk period following birth, a team of researchers from Canada and the US said.
RSV, or respiratory syncytial virus, is one of the leading causes of serious respiratory ill-health in the early years of one's life, and is usually prevalent during early winter months.
Globally, the condition is estimated to cause 36 lakh hospitalisations a year among children aged under five, according to the
World Health Organization
.
Nirsevimab was approved in 2023 by regulatory agencies, including the US' Food and Drug Administration and European Medicines Agency, after the lab-created antibody was found to be safe and effective in clinical trials.
Through national programmes, infants in high-income countries, such as in the US and European Union, have been injected with nirsevimab.
The researchers said that efficacy of nirsevimab seen in the controlled settings of a clinical trial may not fully reflect how the lab-created antibody performs in real-world settings.
Real-world effectiveness studies are essential to evaluate the effectiveness of nirsevimab across diverse infant populations and clinical settings, the team added.
For this study, the researchers analysed 27 previously published studies, which were conducted during the RSV seasons of 2023-2024 across five countries -- France, Italy, Luxembourg, Spain and the US. The team mainly focussed on infants aged under 12 months.
"Nirsevimab is highly effective in preventing RSV-related outcomes in infants, with a pooled real-world effectiveness of 83 per cent against hospitalisation, 81 per cent against ICU admission, and 75 per cent against LRTI (
lower respiratory tract infections
)," the authors wrote.
The lab-created antibody was also found to be more effective among infants aged over three months, compared to those aged under three months.
The researchers noted that nirsevimab is not a vaccine, despite being delivered as an injection.
A monoclonal antibody is created in a lab to mimic how an antibody works, whereas a vaccine empowers the body's immune system to produce an immune response, which involves creating antibodies, they said.
The findings indicate that the benefits of nirsevimab seen in clinical trials could be translated into real-world settings, potentially reducing the burden of RSV disease among infants and use of healthcare resources, the authors said.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
3 hours ago
- Time of India
Khargone woman tests Covid positive post delivery, dies
Indore: A 44-year-old woman from Khargone, who recently gave birth at MTH Hospital, tragically died at MRTB Hospital from intrapartum seizures after testing positive for Covid-19 on Friday. She delivered a healthy baby boy weighing 3.1 kg on May 28, but, succumbed just eight days later. This unfortunate death marks the second Covid-related fatality in Madhya Pradesh amid the current surge in cases. Previously, a 74-year-old woman from Indore, who was also Covid-19 positive, passed away while undergoing treatment for renal failure at Aurobindo Hospital. Indore district epidemiologist Dr Anshul Mishra said, "It's the second death of patients, who tested positive for Covid-19, reported in Indore. The 74-year-old woman was a resident of Indore, while the 44-year-old woman belonged to Khargone." Khargone CMHO Dr ML Sisodiya said, "We have got details of the woman. Her family members will be approached and examined. If any symptoms of Covid-19 are found among them, they will be tested and given the required treatment." Following her delivery, the woman's health rapidly deteriorated. An RT-PCR test on June 5 confirmed that she was Covid-19 positive, leading to her transfer to the isolation ward at MRTB Hospital, senior professor (gynaecology) Dr Sumitra Yadav said. Despite immediate medical intervention, her condition worsened, and she was declared dead at 3:50am the next morning. Dr Yadav explained that the woman suffered a convulsion on the operation table immediately after her delivery. "She experienced a sudden drop in blood pressure and oxygen saturation. Urgent intubation was done," Dr Yadav stated. The patient was diagnosed with placenta previa, a serious pregnancy condition. Compounding her condition were a history of two previous caesarean sections, a transverse lie (abnormal fetal position), and polyhydramnios (excess amniotic fluid). Due to these complications, the delivery was performed via lower segment caesarean section (LSCS). She was also a known case of hypothyroidism. Following her surgery, the patient was moved to the ICU on May 28 at 10:15am. Her condition remained critical, and it further worsened after she tested positive for Covid-19, leading to her transfer to MRTB Hospital's isolation ward where she died, Dr Yadav said. The total number of Covid-19 cases reported in Indore has reached 50 so far including nine patients from other districts. Health officials have confirmed there 26 active cases in the city at present.
Mint
6 hours ago
- Mint
COVID-19 update, 7 June 2025: India's active case count nears 6,000 with 391 new infections; Kerala, Delhi lead surge
Covid-19 Update, June 7: India's active cases of Covid-19 yet saw another increase over the past 24 hours, data from the Union Ministry of Health revealed on Saturday as the grip of the coronavirus continued to rise over the past few weeks. The number of active Covid-19 cases neared the 6,000 mark over the past 24 hours, data showed on Saturday. India's number of active Covid-19 cases has increased to 5,755 in the past day, the Covid dashboard of the health ministry revealed. India has reported 391 Covid-19 cases in the past 24 hours, according to the data. This is a drop from the 498 cases that the country recorded on Friday. The number of Covid-19 patients who have been discharged over the past 24 hours were recorded at 760. This is a decrease from the 764 recoveries recorded on Friday. As many as four people died due to Covid-related issues over the past day, according to the data. The deaths were reported from Kerala, Madhya Pradesh, Tamil Nadu and Maharashtra. In Maharashtra, a pregnant 45-year-old woman died in the hospital after she started having intrapartum seizures after which she became intubated. She later tested Covid-19 positive. Another 59-year-old man in Kerala with lung cancer passed away. The two other patients who died were over 60 years of age and had comorbidities. Kerala recorded most number of Covid-19 cases on Saturday at 127, while one person died in the state. This was followed by Gujarat and Delhi. Gujarat recorded 183 new coronavirus positive cases on Saturday, taking the active count in the state to 822, the health department said. However, no death was reported in the past 24 hours. All the cases which are emerging in Gujarat are of JN.1, LF.7, LF.7.9 and XFG variants of the Omicron family, which causes mild fever and cough, the health department said. Maharashtra on Saturday reported 86 new cases, taking the total count since January to 1,362. Of these new cases, 31 were detected in Pune city and two in its rural parts and 28 tested positive in Mumbai, an official statement said. Uttarakhand recorded four new coronavirus positive cases on Saturday. Seven people have tested positive for Covid-19 in Dehradun on Friday, with the health department tracking down those who came in contact with them. Odisha Education Minister Nityananda Gond said the government is cautious about Covid-19 and that teachers should be trained to prevent Covid-19 infection when exposure to the virus cannot be avoided.
Time of India
7 hours ago
- Time of India
What is RSV and why are infants especially at risk in India?
Respiratory Syncytial Virus, commonly known as RSV, is the leading cause of respiratory illness in children and infants worldwide. In India, RSV has also become a major issue for parents as well as pediatricians, particularly in the post-monsoon and winter seasons when cases surge. Although the nation continues to establish complete surveillance information, existing studies in tertiary care facilities show that RSV contributes 30% to 50% of bronchiolitis and pneumonia incidents in children aged two years and below. RSV is usually responsible for the symptoms of a cold in older children and adults. Nevertheless, in infants—especially those under six months of age, those who were premature at birth, or those with underlying health issues—the virus may cause severe lower respiratory tract infections, including bronchiolitis (inflammation of small airways) and pneumonia. These two diseases usually require hospitalization, and hospitalization rates between 3 and 5 per 100 infants less than one year of age per year have been estimated in India. The risks are not equal throughout the nation. Geographic and socioeconomic variations account for both the risk of and outcome of RSV infection. Children living in lower-income populations or in densely populated urban environments can have increased exposure from lesser access to healthcare, suboptimal ventilation, and slower diagnosis. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Eat 1 Teaspoon Every Night, See What Happens A Week Later [Video] getfittoday Undo Seeing the international burden of RSV, the World Health Organization (WHO) recently supported maternal RSV vaccination as a prevention approach. This entails immunizing pregnant women so that antibodies are passed on to the unborn child, providing immunity in the vulnerable early months of life. Although not yet included in India's Universal Immunization Programme (UIP), Indian health authorities, such as the Indian Academy of Pediatrics, are in the process of evaluating the vaccine's safety, effectiveness, and affordability in India. Phased introduction in high-risk groups could be the initial step. Apart from vaccines, monoclonal antibodies too have been promising in the prevention of RSV-related complications. These provide passive immunity in a single dose of injection. But the big constraint is cost. Without government incentives or being covered under public health schemes, these therapies could prove to be out of reach for the majority of Indian families. Differential pricing models and collaborations with insurance companies will become paramount in order to expand access. More encouragingly, Indian drug makers are not idle either. Bharat Biotech and Serum Institute of India have initiated RSV research programs and are likely to bank on their experience in the production of pediatric and maternal vaccines. Tie-ups with global firms can also open the way for local production of monoclonal antibodies, leading to costs savings as well as wider availability. Experts put wide availability of RSV vaccines and antibodies in India at least 2 to 4 years down the road. Early access could start in corporate or private hospitals dealing with high-risk pregnancies. In the private sector, however, the incorporation of RSV prevention in the national immunization program will be crucial to making RSV vaccines and antibodies accessible and beneficial for all Indian infants—irrespective of birthplace. Article courtesy: Dr. Shreya Dubey - Consultant - Neonatology & Paediatrics, CK Birla Hospital, Gurugram Russia's Lavrov Sounds Alarm Over German Army Buildup Plan; 'Very Worrying, Need To…' One step to a healthier you—join Times Health+ Yoga and feel the change
